| 1 |
A Phase 1 Combination Study of 177Lu Pocuvotide Satetraxetan and Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| RPT |
mCRPC |
PSMA & PD-1 |
Phase 1 |
Cellbion Co., Ltd. |
RS-2026-25502433 |
|
| 2 |
Preclinical evaluation of the peptide candidate CBT-001-2334 for the development of CAIX-targeted radiopharmaceuticals for tumor diagnosis and therapy |
| RPT |
Solid tumor |
CAIX |
Preclinical |
C-BIOMEX |
RS-2026-25501541 |
|
| 3 |
Development of an Optimized Radiopharmaceutical for Targeted Therapy of Metastatic Malignant Melanoma |
| RPT |
Melanoma |
Melanin |
Candidate |
CNCure Co., Ltd. |
RS-2025-25454797 |
|
| 4 |
Development of a Therapeutic Radiopharmaceutical using Alpha Nuclide Targeting mCRPC (Metastatic Castration Resistant Prostate Cancer) |
| RPT |
Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Prostate-Specific Membrane Antigen (PSMA) |
Preclinical |
CellBion Co., Ltd. |
RS-2025-25454770 |
|
| 5 |
Nonclinical studies of therapeutic radiopharmaceuticals for ovarian cancer based on nano-drug carriers for global market entry |
| RPT |
Ovarian cancer |
Folate receptor |
Preclinical |
ZTI BIOSCIENCES, INC |
RS-2024-00337888 |
|
| 6 |
Development of a new class of PSMA target radiopharmaceuticals for prostate cancer |
| RPT |
Castration-resistant prostate cancer |
PSMA |
Phase 2 |
FutureChem Co., Ltd. |
RS-2023-00218051 |
|
| 7 |
Clinical development of PSMA target therapeutic radiopharmaceutical for prostate cancer |
| RPT |
Prostate cancer |
PSMA |
Phase 1 |
FutureChem. Co., Ltd. |
HN21C1297 |
|
| 8 |
Development of Novel Radiopharmaceutical for Prostate Specific Membrane Antigen Targeted Therapy |
| RPT |
Prostate cancer |
PSMA |
Phase 2 |
CellBion Co., Ltd. |
HN21C0626 |
|